Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Instituto D Or de Pesquisa e Ensino IDOR

Rio de Janeiro, 22281 100, BrazilNot linked to an institution yet

4running trials
2closed trials

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions: Lung cancer4 trials
Childhood cancers1 trial
Prostate cancer1 trial
Phase: Phase 34 trials
Phase 1/21 trial
Phase 21 trial
Status: Active, not recruiting4 trials
Completed2 trials
Lead sponsor: Janssen Research & Development, LLC5 trials
Pfizer1 trial

Running trials

Active, not recruiting
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314· Phase 1/2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664· Phase 3· Janssen Research & Development, LLC· Source

Closed trials

Completed
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
NCT04083976· Phase 2· Janssen Research & Development, LLC· Source
Completed
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
NCT02003924· Phase 3· Pfizer· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error

Under construction, not live – Instituto D Or de Pesquisa e Ensino IDOR: trial site – Frontlight Research